Plain-English translation of NCT07272499 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether a combination of three medications — , lisaftoclax, and rituximab — can help people with newly diagnosed, high-risk mantle cell lymphoma live longer and have better responses to treatment. Mantle cell lymphoma is an aggressive type of blood cancer, and this combination brings together three different types of medicines that work in different ways to fight the cancer.
Standard chemotherapy doesn't work well enough for people with high-risk mantle cell lymphoma. Recent research showed that combining these three types of medications was very effective in other groups of patients, so doctors want to test whether this approach can help more people, especially those with the most dangerous forms of this cancer.
You likely qualify if…
You likely don't qualify if…
You will take three medications by mouth daily for 6 months (the induction phase), with one medication given by IV infusion once during each 4-week cycle. If your cancer responds to treatment, you will then continue taking two of the medications by mouth for up to 2 additional years (the maintenance phase). You will have regular clinic visits, blood tests, and scans to monitor how well the treatment is working and check for any side effects.
AI-generated summary from trial data · Jun 24, 2026 · Not medical advice
China